Digoxin

Generic Name
Digoxin
Brand Names
Digox, Lanoxin
Drug Type
Small Molecule
Chemical Formula
C41H64O14
CAS Number
20830-75-5
Unique Ingredient Identifier
73K4184T59
Background

Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

This drug originates from the foxglove plant, also known as the Digitalis plant, studied by William Withering, an English physician and botanist in the 1780s. Prior to this, a Welsh family, historically referred to as the Physicians of Myddvai, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.

Indication

Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.

In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.

Associated Conditions
Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure
Associated Therapies
-

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

First Posted Date
2016-02-18
Last Posted Date
2017-11-24
Lead Sponsor
Tobira Therapeutics, Inc.
Target Recruit Count
36
Registration Number
NCT02685462

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

First Posted Date
2015-12-30
Last Posted Date
2017-01-27
Lead Sponsor
Intarcia Therapeutics
Target Recruit Count
33
Registration Number
NCT02641899
Locations
🇺🇸

Quintiles, Overland Park, Kansas, United States

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

First Posted Date
2015-12-10
Last Posted Date
2020-12-10
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
32
Registration Number
NCT02626234
Locations
🇺🇸

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

🇬🇧

Novartis Investigative Site, Manchester, United Kingdom

🇺🇸

Emory University School of Medicine/Winship Cancer Institute Phase 1 Working Group, Atlanta, Georgia, United States

Digoxin Short Term Treatment Assessment Randomized Trial in AHF

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2015-09-09
Last Posted Date
2023-12-18
Lead Sponsor
University of Monastir
Target Recruit Count
500
Registration Number
NCT02544815
Locations
🇹🇳

Fattouma Bourguiba University Hospital, Monastir, Tunisia

🇹🇳

Sahloul University Hospital, Hammam sousse, Sousse, Tunisia

Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-06-15
Last Posted Date
2017-01-24
Lead Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Target Recruit Count
16
Registration Number
NCT02472236
Locations
🇨🇳

The first affiliate of Xi'an Jiaotong University, Xi'an, Shanxi, China

The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-05-22
Last Posted Date
2016-11-30
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
16
Registration Number
NCT02451527
Locations
🇨🇳

The First Affiliated Hospital of Xi'an Jiaotong University, Xian, Shaanxi, China

Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-03-18
Last Posted Date
2021-06-18
Lead Sponsor
University of Birmingham
Target Recruit Count
161
Registration Number
NCT02391337
Locations
🇬🇧

Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom

🇬🇧

City Hospital, Birmingham, West Midlands, United Kingdom

Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam

First Posted Date
2015-02-25
Last Posted Date
2016-05-23
Lead Sponsor
Takeda
Target Recruit Count
34
Registration Number
NCT02370615

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

First Posted Date
2015-01-26
Last Posted Date
2015-03-10
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT02345304
Locations
🇩🇪

1344.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

© Copyright 2024. All Rights Reserved by MedPath